ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1472

Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience

Asif Hitawala1, Zerai Manna2, Yenealem Temesgen-Oyelakin3, Elaine Poncio3, Christopher Koh4, sarfaraz Hasni2 and Theo Heller4, 1NIDDK/NIH, Bethesda, MD, 2Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4NIDDK/Liver disease branch, Bethesda, MD

Meeting: ACR Convergence 2023

Keywords: longitudinal studies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) are known to have hepatic injury (HI), however large-scale longitudinal studies are lacking.We report our experience of HI in SLE patients.

Methods: A retrospective longitudinal single center study was conducted from 1994-2022 to identify patients enrolled in natural history protocol for SLE. Inclusion: 1) Age ≥ 18 years; 2) Diagnosis of SLE based on 1997 American College of Rheumatology revised criteria. Exclusion: Patients with either < 3 visits or < 6 months of follow-up. Demographic, laboratory, medication and liver histology data (when available) were obtained from the electronic medical records. Patients were divided into two categories- with and without HI. HI was divided into 5 categories- persistent hepatocellular injury, transient hepatocellular injury, persistent cholestatic injury, transient cholestatic injury and mixed. Patients were allowed to be in more than one category. Chi-square test and Kruskal-Wallis tests were used for comparing categorical and numerical variables, respectively. P-value < 0.05 was considered statistically significant and R software was used for all statistical analyses.

Results: Out of 1106 patients, 636 patients were included in the final cohort, with median duration of follow-up of 9.7 yrs (IQR 4.15-16.96). Mean age was 53.85 yrs (±15.31) and majority were females (555, 87.26%). A large proportion of patients (303, 47.64%) developed HI- persistent hepatocellular injury, transient hepatocellular injury, persistent cholestatic injury, transient cholestatic injury and mixed injury were present in 91, 174, 55, 78 and 67 patients, respectively. Patients with HI were older, more likely to be male, Asian, Caucasian or Hispanic and less likely to be African American (Table 1). Patients with HI also had longer follow-up. In majority of patients (230, 75.91%), the cause of HI could not be identified. Of the remaining 73 patients, non-alcoholic fatty liver disease was the most common, followed by drug-induced liver injury, SLE flare and non-alcoholic steatohepatitis (Table 2). On univariable analysis, apart from liver enzymes, age, gender, race, date of SLE diagnosis, duration of follow-up, iron, ferritin, ESR, and ANA were significantly associated with HI (Table 3). However, on multivariable analysis, only alkaline phosphatase, alanine transaminase and duration of follow-up remained associated with higher odds of HI, while older age was associated with lower odds, suggesting patients tend to develop HI at a younger age. All-cause mortality was higher in patients with HI.

Conclusion: A large number of SLE patients develop HI during the course of the disease, with transient hepatocellular injury the most common type of HI. While males and Asians, Caucasians and Hispanics seem to be at a higher risk, African-Americans seem to be at lower risk of HI, although in a majority of patients the cause remains unclear. Fatty liver disease was the most common cause of liver disease, although patients were also found to have autoimmune hepatitis, primary biliary cholangitis and nodular regenerative hyperplasia. Higher mortality in patients with liver disease might suggest a more severe SLE disease course and consequently worse outcomes.

Supporting image 1

Table 1: Baseline Characteristics

Supporting image 2

Table 2; Etiologies of Hepatic Injury

Supporting image 3

Univariable and Multivariable Analysis of Hepatic Injury


Disclosures: A. Hitawala: None; Z. Manna: None; Y. Temesgen-Oyelakin: None; E. Poncio: None; C. Koh: None; s. Hasni: AstraZeneca, 5; T. Heller: None.

To cite this abstract in AMA style:

Hitawala A, Manna Z, Temesgen-Oyelakin Y, Poncio E, Koh C, Hasni s, Heller T. Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-hepatic-injury-in-patients-with-systemic-lupus-erythematosus-a-28-year-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-hepatic-injury-in-patients-with-systemic-lupus-erythematosus-a-28-year-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology